Summary
Botulinum toxin (BoNT) drugs have been used with remarkable success for more than 20 years generating an industry with annual sales in excess of 1 billion US dollars. However, BoNT drugs are not at the end of their development cycle. Product development will focus on an improved antigenicity by increasing the specific biological activity, by separation of complexing proteins, by introduction of high affinity BoNT or by shielding of antigenic BoNT epitopes. Other development will include transdermal application, drug labeling for imaging guided applications, ready made solutions, and drug stability. New BoNT drugs are already offering some of these improved features. BoNT drugs are safe and effective, but need continuous development.
Similar content being viewed by others
References
D Dressler R Benecke (2003) ArticleTitleAutonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis Eur Neurol 49 34–38 Occurrence Handle12464716 Occurrence Handle10.1159/000067023 Occurrence Handle1:CAS:528:DC%2BD38Xpt1Wis7s%3D
D Dressler H Bigalke (2004) ArticleTitleAntibody-induced failure of botulinum toxin type B therapy in de novo patients Eur Neurol 52 132–135 Occurrence Handle15479980 Occurrence Handle10.1159/000081463 Occurrence Handle1:CAS:528:DC%2BD2cXhtVSmsrrE
D Dressler G Dirnberger (2000) ArticleTitleBotulinum toxin therapy: risk factors for therapy failure Mov Disord 15 IssueIDSuppl 2 51
D Dressler M Hallett (2006) ArticleTitleImmunological aspects of Botox®, Dysport®, and NeuroBloc®/Myobloc®/MyoBloc™ Eur J Neurol 13 IssueIDSuppl 1 11–15 Occurrence Handle16417592 Occurrence Handle10.1111/j.1468-1331.2006.01439.x
J Jankovic KD Vuong J Ahsan (2003) ArticleTitleComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology 60 1186–1188 Occurrence Handle12682332 Occurrence Handle1:STN:280:DC%2BD3s7msFSgtw%3D%3D
JC Lee K Yokota H Arimitsu HJ Hwang Y Sakaguchi J Cui K Takeshi T Watanabe T Ohyama K Oguma (2005) ArticleTitleProduction of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin Microbiology 151 3739–3747 Occurrence Handle16272395 Occurrence Handle10.1099/mic.0.28421-0 Occurrence Handle1:CAS:528:DC%2BD2MXht1Cms7bO
P Moore M Naumann (2003) Handbook of botulinum toxin treatment EditionNumber2 Blackwell Science Malden, MA
AB Scott (1980) ArticleTitleBotulinum toxin injection into extraocular muscles as an alternative to strabismus surgery J Pediatr Ophthalmol Strabismus 17 21–25 Occurrence Handle7365644 Occurrence Handle1:STN:280:Bi%2BC283ktlc%3D
Author information
Authors and Affiliations
Corresponding author
Additional information
Correspondence: Dirk Dressler, Department of Neurology, Rostock University, Gehlsheimer Str. 20, 18147 Rostock, Germany
Rights and permissions
About this article
Cite this article
Dressler, D. Botulinum toxin drugs: future developments. J Neural Transm 115, 575–577 (2008). https://doi.org/10.1007/s00702-007-0863-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-007-0863-9